Lanean...
Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection
Liraglutide, a Glucagon-Like Peptide 1 (GLP-1) receptor agonist, is used as a treatment for Type 2 Diabetes Mellitus and obesity because it improves glycemia and decreases food intake. Here, we tested whether chronic activation of the GLP-1 receptor system with liraglutide would induce decreases in...
Gorde:
| Argitaratua izan da: | Physiol Behav |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5545097/ https://ncbi.nlm.nih.gov/pubmed/28366815 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.physbeh.2017.03.045 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|